



(11) **EP 1 606 232 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
03.11.2010 Bulletin 2010/44

(51) Int Cl.:
C07K 1/14 ^(2006.01) **C07K 1/30** ^(2006.01)
C07B 63/00 ^(2006.01) **C07K 2/00** ^(2006.01)
C07K 14/495 ^(2006.01) **C07K 14/65** ^(2006.01)

(21) Application number: **04722118.9**

(86) International application number:
PCT/NZ2004/000058

(22) Date of filing: **19.03.2004**

(87) International publication number:
WO 2004/083154 (30.09.2004 Gazette 2004/40)

(54) **IMPROVED EXTRACTION PROCESS**

VERBESSERTES EXTRAKTIONSVERFAHREN

PROCESSUS D'EXTRACTION AMELIORE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **21.03.2003 NZ 52486803**

(43) Date of publication of application:
21.12.2005 Bulletin 2005/51

(73) Proprietor: **Velvet Antler Research New Zealand
Limited
Mosgiel (NZ)**

(72) Inventor: **HAINES, Stephen
Mosgiel (NZ)**

(74) Representative: **Elsy, David et al
Withers & Rogers LLP
Goldings House
2 Hays Lane
London SE1 2HW (GB)**

(56) References cited:
**EP-A2- 0 273 121 WO-A-97/00269
US-A1- 6 093 402**

- **SCOPES R.K.: 'Protein purification - principles and practice' SPRINGER-VERLAG 1994, pages 85 - 92, XP002904860 -& SCOPES R.K.: 'Protein purification - principles and practice' SPRINGER-VERLAG 1994, pages 95 - 101, XP002904861**

EP 1 606 232 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**TECHNICAL FIELD**

5 **[0001]** The present invention relates to an improved extraction process. In particular, the present invention relates to an improved extraction process for isolating low molecular weight peptides from animal tissue.

BACKGROUND ART

10 **[0002]** In the health food and biomedical markets there exists a growing demand for extracts of animal products that contain enriched levels of growth factors and other low molecular weight polypeptides. This demand stems from the enhanced bioactivity, and often greater solubility and stability, of the smaller polypeptides relative to the large proteins present in the tissue or other source material. In particular, low molecular weight peptide and growth factor extracts have properties making them suitable for a number of diverse applications including medical (e.g. wound healing) products, ingredients in dietary supplements, cosmetics and cell growth media.

15 **[0003]** A variety of standard methods for aqueous extraction of animal tissues have been developed and used widely for isolation of proteins, Scopes R.K. (1987). Typically aqueous extraction involves using some method for breaking up cells, such as ultrasound or mechanical disruption (in a blender), in the presence of water or an aqueous salt or buffer. The pH of the extraction system is sometimes manipulated, or detergents and other additives used, in order to enhance the solubility of specific target proteins (e.g. membrane-associated enzymes). However, typically the initial total protein extract will contain proteins having a wide range of molecular weights. Further processing steps are then required for selective enrichment of growth factors and other low molecular weight polypeptides in the total protein extracts.

20 **[0004]** Commercial production of growth factor-enriched tissue extracts enriched with low molecular weight peptides requires the availability of practical, cost effective methods for removal of unwanted higher molecular weight proteins from the mixtures. Current methods that are applicable on an industrial scale for fractionation of tissue extracts and other animal-derived material (e.g. blood, milk, colostrum), with potential enrichment of growth factors, include:

- Ultrafiltration
- 30 • Gel filtration chromatography (GFC) (also known as size exclusion chromatography)
- Other chromatographic fractionation systems (e.g. ion exchange, hydrophobic interaction, affinity)
- Liquid phase partitioning in multiphasic systems
- 35 • Precipitation from aqueous solution (i.e. from the liquid phase) using water miscible organic solvents (ethanol, acetone), typically the organic solvent is ice cold sometimes with the addition of immiscible organic solvents (chloroform) to enhance the denaturing effect, Scopes, R.K. (1987).
- 40 • Salting out with neutral salts or amino acids

[0005] However, in most instances these methods have been used to isolate enzymes and other moderately large proteins, rather than the concentration of growth factors and other peptides. For example, precipitation using cold ethanol is the basis of the traditional Cohn fractionation method for preparation of albumin and other proteins from plasma.

45 **[0006]** Consequently, these methods have disadvantages, or are otherwise not well suited, for general enrichment of growth factors and other low molecular weight polypeptides.

[0007] Ultrafiltration and GFC both require expensive capital investment, are sensitive to fouling, and the latter results in dilution of the desired low molecular weight fraction. Other chromatographic fractionation systems can also be expensive to operate, and tend to be used to purify specific peptides rather than isolate high or low molecular weight fractions.

50 **[0008]** Liquid phase partitioning in multiphase systems (e. g. cloud point extraction and aqueous two-phase systems) is particularly of use when a labile protein (e. g. an enzyme) is the desired product as the protein is retained throughout in an aqueous environment, Skopes R. K.(1987), Tani H et al. (1997). This assists with the retention of the biological activity of the molecule. The disadvantage of the method is that the desired product is obtained in the presence of large amounts of detergents, salts and/or water-soluble polymers which must be removed. This adds to the cost of the process and frequently necessitates the use of additional steps such as ultrafiltration.

55 **[0009]** The other remaining methods also all result in addition of large amounts of other chemicals (organic solvent, amino acids or salts) which must be removed from the solution of polypeptide. As well as increasing costs due to the need for additional processing steps, these may introduce safety issues as in the case of the use of large volumes of

flammable and/or toxic solvents. The safe handling and eventual removal of such solvents requires the use of specially designed, and typically very expensive, processing facilities and equipment.

[0010] US 6,093,402 discloses citrus amanatsudaikai extract to isolate a peptide. EP0273121 discloses oligopeptides extracted from bovine blood and to a method for their preparation and usage. WO97/00269 discloses a family of linear antimicrobial peptides from hagfish intestine. WO97/00269 also discloses the chemical sequences of these proteins.

[0011] It is acknowledged that the term 'comprise' may, under varying jurisdictions, be attributed with either an exclusive or an inclusive meaning. For the purpose of this specification, and unless otherwise noted, the term 'comprise' shall have an inclusive meaning - i.e. that it will be taken to mean an inclusion of not only the listed components it directly references, but also other non-specified components or elements. This rationale will also be used when the term 'comprised' or 'comprising' is used in relation to one or more steps in a method or process.

[0012] It is an object of the present invention to address the foregoing problems or at least to provide the public with a useful choice.

[0013] Further aspects and advantages of the present invention will become apparent from the ensuing description which is given by way of example only.

DISCLOSURE OF INVENTION

[0014] The shortcomings of these various methods for removal of larger proteins from tissue extracts, when low molecular weight peptides are the peptides of interest, lead the inventors to consider a novel alternative. Namely, the prevention of the initial dissolution of higher molecular weight fraction proteins, by *in situ* denaturation within the tissue, by an organic solvent (preferably ethanol), prior to aqueous extraction. Treatment of solid tissue with organic solvent has been used previously, but specifically for the delipidation and dehydration of the tissue (Scopes, R.K. (1987), Betzing, H. *et al* (1975)) rather than enhancing the concentration of low molecular weight polypeptides in subsequent aqueous extracts. Consequently, further isolating of the LMW peptides is required.

[0015] According to one aspect of the present invention there is provided a process for isolating low molecular weight ("LMW") peptides from tissue *in situ*, comprising the steps of:

a) homogenizing the tissue;

b) mixing the homogenized tissue with an organic solvent to form a fully-wetted slurry;

c) standing or agitating the slurry to denature the proteins *in situ* within the tissue;

d) removing the organic solvent from the tissue;

e) mixing the organic solvent-treated tissue of step d) with a sufficient volume of water or an aqueous solution to extract the peptides;

f) separating a liquid extract from the tissue residue of step e) to obtain an aqueous solution containing the low molecular weight peptide fraction removed from the tissue.

[0016] The term "isolated" means substantially separated, or purified away from, high molecular weight peptides or other unwanted material within the tissue from which the low molecular weight peptides are extracted.

[0017] Throughout this specification the term "low molecular weight peptide" or "LMW peptide" refers to a peptide having an apparent molecular weight of 10,000 Daltons or below.

[0018] Throughout this specification the term "apparent molecular weight" as used herein refers to the molecular weight of a peptide as determined by gel filtration chromatography.

[0019] Throughout this specification the term "total protein extract" as used herein refers to a tissue extract prepared using standard prior art aqueous extraction techniques, such as detailed earlier in the background art discussion, without any attempt to control the molecular weights of the proteins contained in the extract.

[0020] Throughout this specification the term "agitating" or grammatical variations of this term refers to the process of stirring, shaking or irradiating with ultrasound in order to achieving a mixing effect.

[0021] The tissue may be any animal tissue, or other substantially solid animal product (including dried blood, milk or colostrum) from which it is desired to extract LMW peptides.

[0022] In general, the tissue may be homogenised via ultrasound or mechanical disruption so that it is finely divided. For example, the tissue may be homogenized via a mortar and pestle, blender, mill or any other suitable equipment.

[0023] In general, prior to homogenizing, the tissue may first be optionally subjected to a drying pre-step to assist with homogenization or with preservation of the tissue.

[0024] The tissue may be dried by any process which is capable of removing water therefrom, without affecting the properties of the LMW peptides of interest within the tissue.

[0025] In preferred embodiments the tissue may be freeze dried so as to not affect any heat sensitive growth factors.

[0026] The organic solvent may be any organic solvent which does not affect the properties of the LMW peptides of interest.

[0027] In some embodiments the organic solvent may be acetone, acetonitrile, methanol, propan-1-ol, propan-2-ol.

[0028] In preferred embodiments, the organic solvent may be ethanol due to its anti-microbial activity and low toxicity. Most preferably, in the case of dried tissue 70% ethanol may be used.

[0029] In embodiments, where the extraction process of the present invention is used in relation to fresh tissue, sufficient absolute ethanol may be added to provide a total water content of approximately 30% with respect to the volume of ethanol. Optionally, once this water content has been achieved, further 70% ethanol can be added, if required, to create a fully-wetted loose slurry.

[0030] It will be appreciated by those skilled in the art that whilst higher or lower concentrations of ethanol may optionally be used: the maximal anti-microbial activity of ethanol occurs at the preferred concentration of 70% ethanol.

[0031] For ease of reference only the organic solvent will now simply be referred to as being ethanol.

[0032] Throughout this specification the term "fully-wetted" refers to the addition of sufficient liquid to a finely divided solid so as to produce a free flowing slurry.

[0033] The term "liquid phase" as used herein refers to the use of solutions of materials that are normally solids (for example, proteins), so that processing operations are performed entirely with liquids.

[0034] Throughout this specification the term "ambient temperature" shall mean the temperature of the encompassing environment and shall substantially be in the range 10-30°C.

[0035] In general, the fully-wetted slurry may be left to stand or is agitated for a period of at least substantially one hour at an ambient temperature. Most preferably the fully-wetted slurry is left to stand or is agitated at least substantially three or more hours, and at an ambient temperature. However, the performance of this step at a lower temperature (i.e. below that of the ambient environment), if necessary to maintain biological activity of the LMW peptides, is not precluded by this method. In preferred embodiments agitation is the preferred over simply allowing the slurry to stand, as it would be reasonably expected by those skilled in the art to lead to more efficient extraction of soluble components from tissue.

[0036] It will be appreciated by those skilled in the art that the period over which the fully-wetted slurry is left to stand, should be sufficient to allow for the denaturing of the proteins to incur *in situ* within the tissue. As well as to reduce the microbiological loading of the slurry. After the fully-wetted slurry has been left to stand, the ethanol may be removed in a variety of different manners.

[0037] In some embodiments the ethanol may be removed by filtration, centrifugation, or other physical means. However, it should be appreciated that removing ethanol in this manner may result in a lower yield of LMW peptides in the final aqueous solution. As some dissolution of hydrophobic or LMW peptides into the organic solvent may occur.

[0038] Thus, in preferred embodiments the ethanol may be removed via direct evaporation of the organic solvent under vacuum. Most preferably, the evaporation may be achieved using only a gentle heat, so that the temperature remains below substantially 30°C, where preservation of heat sensitive growth factors is an objective.

[0039] Once the ethanol has been removed, the ethanol treated tissue may be fully dried under a high vacuum, for example in a freeze drier or such like. This optional step is recommended where it is desired to remove traces of the organic solvent to facilitate the storage of the tissue at this stage, or to reduce the chances of the traces of organic solvent affecting yield or composition of the LMW peptides obtained in the final water based extraction of the remaining method steps f) or method step g) this later step being detailed below.

[0040] The term "aqueous solution" as used herein refers to a solution in which the solvent used is water and includes aqueous salt or buffer solutions.

[0041] In some preferred embodiments there may be an additional step d1) wherein the solvent treated tissue of step d) may be fully dried prior to undertaking step e).

[0042] The ethanol treated tissue of steps d) or d1) may be mixed with water or with suitable aqueous salt or buffer solution (including to phosphate buffer, citrate buffer, acetate buffer, tris buffer or dilute sodium chloride solution). The resulting mixture should preferably be stirred for substantially one hour. For preservation of growth factors, this should again be performed done at low temperature - i.e. ambient temperature or below.

[0043] It is envisaged that a liquid extract may be separated from the ethanol treated tissue of step e) in a variety of different ways.

[0044] For example, the liquid extract may be separated (i.e. isolated from the solid residue) by:

- decantation;
- centrifugation;

- filtration; or
- other suitable processes as would be apparent to a person skilled in the art.

5 **[0045]** Most preferably, the liquid extract may be clarified by centrifugation, fine filtration or any other suitable clarification process.

[0046] In some preferred embodiments there may be an additional step g) wherein steps e) to f) may be repeated, one or more times, to improve the yield of liquid extract from the tissue residue of step e).

10 **[0047]** Once the solutions of low molecular weight peptides have been obtained from steps f) or g) the liquid extract may optionally be dried for storage or further processing (e.g. product formulation) purposes.

[0048] In preferred embodiments the liquid extract from steps f) or g) may be dried in order to obtain low molecular weight peptides.

15 **[0049]** Most preferably the drying of the solutions of low molecular weight peptides from steps f) or g) may be achieved via freeze drying, although other drying means are possible depending on the properties of the low molecular weight peptides of interest.

[0050] In a further aspect the present invention also provides an isolated mixture of low molecular peptides obtained by the process.

[0051] In yet another aspect the present invention provides the use of an organic solvent to denature proteins *in situ* within tissue as part of an extraction process to isolate low molecular weight peptides from tissue.

20 **[0052]** Thus, preferred embodiments of the LMW *in situ* extraction process of the present invention may have a number of advantages over the prior art extraction processes which can include:

1. Providing a simple method for obtaining an isolated LMW peptide extract with a higher concentration of LMW peptides, than is achieved using the current methods of extraction.

25

2. Providing a method which specifically targets the isolation of LMW peptides.

3. Providing a method which minimises the use of large amounts of expensive or dangerous reagents.

30 **BRIEF DESCRIPTION OF DRAWINGS**

[0053] Further aspects of the present invention will become apparent from the following description which is given by way of example only and with reference to the accompanying drawings in which:

35 Figure 1 (a) Shows a gel filtration chromatography profile of deer velvet total protein extract;

Figure 1 (b) Shows a deer velvet LMW extract prepared using the new *in situ* extraction process of the present invention and an approximate molecular weight scale is given below each chromatogram;

40 Figure 2 A LMW extract prepared by precipitation of high molecular weight proteins from deer velvet total protein extract by addition of cold ethanol in the liquid phase;

Figure 3 Shows gel filtration chromatography profiles of deer velvet LMW extracts prepared using the new *in situ* extraction process, and with varying concentrations of ethanol in the pre-treatment incubation step (which was performed for 3 hours);

45

Figure 4 Shows a graph showing the proportions of LMW and HMW proteins in deer velvet LMW extracts prepared using the new *in situ* extraction process, and with varying concentrations of ethanol in the pre-treatment incubation step (which was performed for 3 hours);

50

Figure 5 Shows gel filtration chromatography profiles of deer velvet LMW extracts prepared using the new *in situ* extraction process, and with varying concentrations of ethanol in the pre-treatment incubation step (which was performed for 16.5 hours);

55 Figure 6 Shows a graph showing the proportions of LMW and HMW proteins in deer velvet LMW extracts prepared using the new *in situ* extraction process, and with varying periods of incubation with 70% ethanol in the pre-treatment incubation step;

- Figure 7** Shows a graph showing the proportions of LMW and HMW proteins in deer velvet LMW extracts prepared using the new *in situ* extraction process, and with varying ratios of 70% ethanol to deer velvet tissue in the pre-treatment incubation step;
- Figure 8** Shows gel filtration chromatography profiles of deer velvet LMW extracts prepared using the new *in situ* extraction process, and with varying organic solvents in the pre-treatment incubation step;
- Figure 9** Shows gel filtration chromatography profiles of deer velvet LMW extracts prepared using the new *in situ* extraction process, and with varying buffers used for the aqueous extraction step;
- Figure 10** Shows gel filtration chromatography profiles of deer placenta LMW extracts prepared using the new *in situ* extraction process, and with varying concentrations of ethanol in the pre-treatment incubation step;
- Figure 11** Shows gel filtration chromatography profiles of deer blood LMW extracts prepared using the new *in situ* extraction process, and with varying concentrations of ethanol in the pre-treatment incubation step;
- Figure 12** Shows gel filtration chromatography profiles of sheep liver LMW extracts prepared using the new *in situ* extraction process, and with varying concentrations of ethanol in the pre-treatment incubation step; and
- Figure 13** Shows gel filtration chromatography profiles of sheep liver LMW extracts prepared using the new *in situ* extraction process, and with varying buffers used for the aqueous extraction step;
- Figure 14** Shows a gel filtration chromatography profile of a LMW extract prepared from frozen deer velvet tissue using the new *in situ* extraction process, compared with a similar extract prepared from freeze-dried deer velvet tissue.

BEST MODES FOR CARRYING OUT THE INVENTION

EXPERIMENTAL

LMW *in situ* Extraction Process - Heat Dried and Freeze-Dried Deer Velvet

[0054] Ground deer velvet powder (5.00 g) derived from the mid-portion of a traditionally (heat) dried antler was weighed into a 500 ml Buchi evaporating flask. Sufficient 70% ethanol (~30 ml) was added to create a mobile slurry and the mixture was stirred at ambient temperature (20°C) on a magnetic stirrer for one hour. The solvent was then removed by rotary evaporation using a Buchi Rotavapor with a 30°C water bath. Traces of residual solvent were removed under high vacuum by use of an oil pump (Edwards) for one hour. De-ionised water (100 ml) was added to the dried residue and the mixture was stirred at ambient temperature (20°C) on a magnetic stirrer for three hours. Following filtration through glass fibre filter paper (Whatman GF/A) the filtrate was centrifuged at 14,600 g for 30 minutes at 4°C. The supernatant was decanted into a glass bottle and then shell frozen and freeze-dried in a cabinet freeze drier (Cuddon) to provide the LMW Extract of Deer Velvet (0.297 g, 5.9% yield) as a brown slightly "sticky" solid. The IGF-1 content of the LMW extract obtained was measured at 0.32 µg/g - refer Table 1.

[0055] The above extraction process was repeated with a composite ground deer velvet powder (5.00 g) derived from freeze-dried antlers. The LMW Extract (0.312 g, 6.2%) was obtained as a free-flowing brown solid. The IGF-1 content of the LMW extract obtained was measured at 3.4 µg/g - refer Table 1.

Table 1. IGF-1 and TGFβ₂ concentrations in the raw material (i.e. velvet powder) and in LMW extract obtained from the raw material by the process of the present invention.

Growth Factor	Velvet	Velvet Powder	LMW Extract
IGF-1	Heat Processed	0.18 µg/g	0.32 µg/g
	Freeze Dried	1.1 µg/g	3.4 µg/g
TGFβ ₂	Heat Processed	7.9 ng/g	47.6 ng/g

Small Scale LMW *in situ* Extraction Process Used in Comparisons of Extraction Conditions

[0056] An accurately weighed amount (500 mg) of tissue (deer velvet, deer placenta, sheep liver) or freeze-dried deer

blood was added to a glass tube fitted with a teflon-lined cap. Sufficient organic solvent was added to provide the required ratio (v/w) with respect to the solid material, and the mixture was agitated on a Vibramax mixer (IKA) for the required period of time at ambient temperature (20°C). In most instances, and unless otherwise stated, 3 ml of solvent was added (6:1 ratio, v/w), and mixing was performed for 3 hours. The bulk of the organic solvent was then removed using a vacuum centrifuge (Heto) and remaining traces of organic solvent were removed under high vacuum using a freeze-drier (FTS).

[0057] To the organic solvent-treated test material was added 10 ml of aqueous buffer. In most instances, and unless otherwise stated, the buffer used was 0.05M phosphate buffer (pH 6.9). The mixture was agitated on a Vibramax mixer (IKA) for 1 hour at ambient temperature (20°C), and was then centrifuged at 2,000 g for 15 minutes at 4°C. The supernatant was transferred to a clean tube and was centrifuged at 40,000 g for 15 minutes at 4°C. The fully clarified supernatant was then aliquoted into clean tubes prior to analysis by GFC (as detailed below) or for growth factors. In some experiments, a 5.0 ml aliquot was also fully dried in pre-weighed tubes using a vacuum oven for determination of extract yields.

[0058] In most experiments, the test material was also extracted with aqueous buffer, as detailed above, without prior treatment with organic solvent. These samples served as control samples to determine the efficiency of removal of high molecular weight proteins by the solvent pre-treatment.

Analysis of Low Molecular Weight Extracts

[0059] The low molecular weight extracts were analysed by GFC on a Superose 12 HR 10/30 column (Amersham Biosciences) using either 0.05M phosphate buffer (pH 6.9) containing 0.3M sodium chloride and 0.05% sodium azide, or 0.05M ammonium bicarbonate for elution. Solid extract samples were dissolved in phosphate buffer at a concentration of approximately 5 mg/ml and 10 µl of each solution were injected onto the column and eluted at a flow rate of 0.75 ml/min. Extract solutions prepared using the small scale LMW *in situ* extraction process were directly injected (10 µl) and eluted under similar conditions. Proteins were detected by measurement of UV absorption at 280 nm.

[0060] Molecular weight calibration of the Superose 12 column was performed by separation of a standard mixture of known proteins of known molecular weights under the above conditions. A calibration curve was then constructed by plotting the logarithm of protein molecular weight against retention time. Apparent molecular weights of eluted protein peaks were determined by interpolation using the calibration curve.

[0061] An automated data processing method was developed using Turbochrom 4.1 (PE Nelson) for comparison of the proportions of low molecular weight proteins and of high molecular weight in the extracts. The method summed the areas of all of the peaks having retention times less than 20.5 minutes ("high molecular weight" peaks, due to proteins having molecular weights greater than approximately 8,000 Daltons) and those with retention times greater than 20.5 minutes ("low molecular weight" peaks, due to proteins having molecular weights less than approximately 8,000 Daltons) in chromatograms of samples eluted using phosphate buffer. For samples eluted with ammonium bicarbonate, the equivalent split between high molecular weight and low molecular weight peaks was performed at a retention time of 18.5 minutes

Prior Art - Preparation of Deer Velvet Total Protein Extract for GFC Analysis

[0062] Freeze-dried deer velvet powder (0.1 g) was briefly mixed with 0.05M phosphate buffer (pH 6.9, 3 ml) by use of a vortex mixer. Following centrifugation at 2,000 g for 5 minutes the mixture was sonicated in an ultrasound cleaning bath (Crest Ultrasonics) for 1 hour at 20°C. The total protein extract thus prepared was clarified by centrifugation at 12,700 g for 15 minutes at 4°C. The supernatant was then directly analysed by GFC - refer Figure 1a). The total protein extract procedure was based on the prior art methods for extraction of proteins as outlined in Scopes, R.K. (1987).

Prior Art - Precipitation of High Molecular Weight Proteins by Ethanol from Deer Velvet Total Protein Extract in the Liquid Phase for GFC Analysis.

[0063] A total protein extract of deer velvet was prepared by gently shaking dried deer velvet powder (10 g) in de-ionised water (100 ml) for 3 hours at ambient temperature. The mixture was centrifuged at 2,100 g for 15 minutes and the supernatant was decanted into a second centrifuge bottle. This was centrifuged at 21,000 g for 15 minutes in order to clarify the water extract, which was then chilled to 4°C. Cold 100% ethanol (3 volumes) was gradually added with constant stirring. The cloudy mixture was centrifuged at 21,000 g for 30 minutes at 4°C to remove the precipitated protein. The supernatant was then evaporated to dryness on a Buchi rotary evaporator prior to analysis by GFC - refer Figure 2. The total protein extract procedure was based on the prior art methods for extraction of proteins as outlined in Scopes, R.K. (1987).

IGF-1 Analysis

[0064] Samples were analysed for insulin-like growth factor 1 (IGF-1) by Endolab (Canterbury Health Laboratories) using a radioimmunoassay for human IGF-1. The assay had an ED₅₀ of 0.39 µg/g and a detection limit of 0.02 µg/g for freeze dried extract samples. For extract solutions, the ED₅₀ of the assay was 50 µg/L and the detection limit was 4.1 µg/L.

IGF-2 Analysis

[0065] Samples of extract solutions were analysed for insulin-like growth factor 2 (IGF-2) by Endolab (Canterbury Health Laboratories) using a radioimmunoassay for human IGF-2. The assay had an ED₅₀ of 1132 µg/L and a detection limit of 32 µg/L.

EGF-like Activity Analysis

[0066] Samples of extract solutions were analysed for epidermal growth factor-like (EGF-like) activity using a radio-receptor assay. The assay measures the ability of substances in the sample to displace radioactively labelled mouse EGF (Amersham) from its receptor on A431 cells (epidermoid carcinoma cell line) in culture. Because other growth factors may bind to the EGF receptor, the combined activity is measured as EGF-like activity.

TGFβ₁ Analysis

[0067] Samples were analysed for transforming growth factor β₁ (TGFβ₁) using the E_{max}® Immunoassay System (Promega Corporation). The assay was specific for TGFβ₁ (≤ 1.6% cross reactivity with TGFβ₂ and ≤ 0.7% TGFβ₃) and had a detection limit of 32 pg/ml.

TGFβ₂ Analysis

[0068] Samples were analysed for transforming growth factor β₂ (TGFβ₂) using the E_{max}® Immunoassay System (Promega Corporation). The assay was specific for TGFβ₂ (≤ 3% cross reactivity with TGFβ₁ and TGFβ₃) and had a detection limit of 32 pg/ml (equivalent to 0.32 ng/g in solid samples).

RESULTS**IGF-1 and TGFβ₂**

[0069] A comparison between the IGF-1 and TGFβ₂ contents of low molecular weight (i.e. new process) extracts prepared from freeze dried and/or heat processed deer velvet powder using the new extraction process are given in Table 1 above. In each case the LMW extracts prepared by the new method had higher concentrations of immunoreactive IGF-1 and TGFβ₂ than was measured in the deer velvet powders from which they were prepared.

Molecular Weight Distribution in Deer Velvet Low Molecular Weight Extract Prepared Using the New Process of the Present Invention

[0070] The gel filtration profile of a water extract of deer velvet powder pre-treated with 70% ethanol (i.e. prepared using the new process) is compared with a comparable extract of untreated velvet powder in Figure 1. As can be seen from Figure 1(a), proteins with apparent molecular weights greater than 10,000 Daltons comprise the bulk of water-based total protein extract obtained from deer velvet at non-elevated temperatures. In comparison, essentially all of these higher molecular weight proteins are absent in the low molecular weight extract prepared using the new ethanol pre-treatment process (Figure 1(b)).

[0071] Precipitation of high molecular weight proteins from standard aqueous deer velvet extract in order to isolate LMW peptides was performed in the liquid phase. This process was undertaken in order to compare the weight distribution of proteins removed by this standard prior art protein chemistry technique with that of the new process of the present invention. As shown in Figure 2, addition of a 3:1 ratio of ethanol to an aqueous solution of velvet total protein extract also resulted in essentially complete removal of proteins having molecular weights over 10,000 Daltons. The close similarity between the two GFC chromatograms in Figures 1(b) and 2 demonstrates that, in the new extraction process of the present invention, ethanol renders the same spectrum of higher molecular weight proteins insoluble (*in situ* within the tissue) as it does in the liquid phase.

The Effect of the Concentration of Ethanol Used in the New Process of the Present Invention

[0072] The gel filtration chromatography profiles of freeze-dried deer velvet samples extracted with 0.05M phosphate buffer (pH 6.9) following pre-treatment for 3 hours with a 6:1 (v/w) ratio of 30%, 40%, 50%, 60%, 70%, 80% or 90% ethanol, or without pre-treatment, are shown in Figure 3. This figure demonstrates that at low concentrations (30%, 40%) and at high concentration (90%) of ethanol, the removal of high molecular weight proteins is less efficient than at intermediate concentrations (50-80%).

[0073] As shown in Figure 4, the percentage of the total combined peak area that is due to low molecular weight proteins reaches a maximum at around 60-70% ethanol. The absolute area (expressed in V.sec) of the low molecular weight peaks, which is proportional to the combined concentrations of the substituent proteins, declines slightly as the concentration of ethanol is increased from 30% to 90%. In contrast, the absolute area (expressed in V.sec) of the high molecular weight peaks declines sharply as the concentration of ethanol is increased from 30 to 50%, is stable at a low level in the range 50-80% ethanol, and then increases again slightly in the sample prepared using 90% ethanol.

The Effect of the Incubation Time With Ethanol in the New Process of the Present Invention

[0074] The above experiment was repeated using overnight (16.5 hours) pre-treatment of the velvet with the various concentrations of ethanol prior to buffer extraction, instead of 3 hours pre-treatment. As can be seen by comparing Figure 5 with Figure 3, the increased pre-treatment period resulted in only a very slight change in the gel filtration chromatography profiles of the extract solutions. The most evident change is the more efficient removal of high molecular weight proteins that elute from the chromatography column prior to 17 minutes, relative to samples prepared using the 3 hour pre-treatment period.

[0075] The result of varying the incubation time with 70% ethanol on the proportions of low molecular weight and high molecular weight proteins is shown in Figure 6. The absolute peak area (in V.sec) of the low molecular weight proteins remained essentially constant for incubation periods between 30 minutes and over 16 hours (overnight), but as a proportion these peaks slightly increased with time. This was due to a gradual concomitant decline in the absolute peak area (in V.sec) of the high molecular weight proteins, due to more efficient removal of these protein with increased ethanol incubation times.

The Effect of the Ratio of Ethanol Used in the New Process of the Present Invention

[0076] Figure 7 shows the effect of varying the ratio of 70% ethanol used in the new process, between 2:1 and 10:1 (v/w) with respect to the amount of freeze-dried deer velvet tissue extracted. The proportions of low molecular weight and high molecular weight peaks in the final extract remain moderately constant across the whole range, but the absolute peak areas steadily decline. The effect is greatest on the area of the peaks due to low molecular weight proteins, which indicates a reduction in yield of these proteins with increasing ratio of ethanol to tissue.

The Effect of the Organic Solvent Used in the New Process of the Present Invention

[0077] Figure 8 compares the effect of using 70% acetonitrile, 70% acetone, 70% propan-2-ol or 70% methanol instead of 70% ethanol for pre-treatment of freeze-dried deer velvet on the protein profiles of the resultant phosphate buffer extracts. A very similar range of high molecular proteins is missing in each of the extracts, showing that each solvent is effective in the new process.

The Effect of the Aqueous Buffer Used in the New Process of the Present Invention

[0078] Figure 9 compares the effect of using water, 0.05M sodium chloride, 0.05M citrate buffer (pH 4.1), 0.05M acetate buffer (pH 4.9), 0.05M tris buffer (pH 7.8) or 0.05M carbonate buffer (pH 10.0) instead of 0.05M phosphate buffer (pH 6.9) for the aqueous extraction on the protein profiles of the resultant extracts. A very similar range of proteins is present in the extracts prepared at pHs near neutrality (using water, sodium chloride, or tris or phosphate buffers). However, fewer high molecular weight proteins are present in extracts prepared at lower pH (using citrate or acetate buffers), while in the extract prepared at higher pH (using carbonate buffer) a greater range of high molecular weight proteins is evident in the protein profile.

[0079] The yields and growth factor contents of each of the above extracts are given below in Table 2. In each case the yield has been calculated as the dry weight of the extract after correction for the content of added salts, and is expressed as a percentage of the starting weight of freeze-dried deer velvet powder. All extracts contained measurable levels of growth factors, although these varied according to the pH of the aqueous extraction medium. EGF-like activity was particularly high in extracts prepared at low pH (using citrate or acetate buffers) or high pH (using carbonate buffer).

Table 2. Yields, IGF-1, IGF-1, TGF β_1 , TGF β_2 and EGF-like concentrations in extracts of deer velvet powder derived via the LMW extraction process of the present invention.

Buffer	Yield	IGF-1 (ng/ml)	IGF-2 (ng/ml)	TGF β_1 (ng/ml)	TGF β_2 (ng/ml)	EGF-like (μ g/ml)
Water	5.0%	11.5	64	0.31	0.53	75
Sodium Chloride	7.7%	14.7	88	0.15	0.35	51
Citrate (pH 4.1)	13.5%	9.5	77	0.60	0.57	750
Acetate (pH 4.9)	9.4%	7.5	88	0.12	0.06	623
Phosphate (pH 6.9)	6.3%	13.7	67	0.44	0.22	90
Tris (pH 7.8)	8.6%	16.0	61	0.21	0.44	0
Carbonate (pH 10)	7.3%	25.1	58	0.46	0.54	643

Use of the New Process With Materials Other Than Deer Velvet

[0080] The gel filtration chromatography profiles of freeze-dried deer placenta, freeze-dried deer blood and of freeze-dried sheep liver samples extracted with 0.05M phosphate buffer (pH 6.9) following pre-treatment for 3 hours with a 6:1 (v/w) ratio of 30%, 40%, 50%, 60%, 70%, 80% or 90% ethanol, or without pre-treatment, are shown in Figures 10, 11 and 12, respectively. These demonstrate that pre-treatments with a range of ethanol concentrations (especially 70% ethanol) are effective for reducing the proportion of high molecular weight proteins in aqueous extracts prepared from these materials, similar to freeze-dried deer velvet antler.

[0081] The effect of the buffer used for the aqueous extraction of sheep liver following pre-treatment for 3 hours with a 6:1 (v/w) ratio of 70% ethanol is shown in Figure 13. As for deer velvet, the extraction of high molecular proteins is least evident from sheep liver when the aqueous extraction is performed at acidic pH (using citrate or acetate buffers).

[0082] The new process is thus shown to be applicable to tissues and materials other than deer velvet.

Use of Frozen Deer Velvet Tissue in the New Process

[0083] Figure 14 shows the gel filtration profile of a LMW extract prepared from a sample of minced frozen deer velvet tissue using the new extraction process, compared to that of a similar extract prepared from freeze-dried velvet. Essentially no high molecular weight proteins are evident in the protein profile of the extract from the frozen sample. This demonstrates that the new process significantly reduces the proportion of high molecular weight proteins in aqueous extracts derived from frozen tissue similar to that from dried tissue.

Discussion

[0084] We have shown that the molecular weight distribution of proteins in aqueous extracts prepared from tissue that has been pre-treated with an organic solvent (ethanol) is similar to that obtained following precipitation of high molecular weight proteins from aqueous solutions of standard total protein extracts by addition of the solvent in the cold.

[0085] The new process has been exemplified by the use of ethanol, acetonitrile, acetone, methanol, and propan-2-ol, but other solvents (including propan-1-ol, butan-1-ol) would reasonably be expected to be usable.

[0086] Key advantages of the new process relative to the liquid phase one are that it

- uses much less organic solvent;
- does not result in dilution of the tissue extract.

[0087] This reduces the hazards involved in the use of a flammable solvent and also reduces liquid handling problems. Furthermore the necessity for a separate clarification step to remove precipitated proteins is removed by the new process. Instead, the high molecular weight proteins are simply rendered insoluble *in situ* within the tissue. Subsequent extraction under aqueous conditions then results in solubilisation of only low molecular weight proteins and peptides.

[0088] A key reason for the preferred use of ethanol as the organic solvent in the new process is due to its anti-microbial activity (particularly at a concentration of 70%). This has the desirable effect of reducing the bacterial loading of the tissue raw material immediately prior to the aqueous extraction.

[0089] The high levels of IGF-1, IGF-2, TGF β_1 , TGF β_2 and EGF-like activity in the LMW extracts of deer velvet show that growth factor activity is retained by the new extraction process. It is thus reasonable to expect that the level of other growth factors will also be enriched in extracts of tissues following the pre-treatment with ethanol.

[0090] The new process has been exemplified by the use of deer velvet, deer placenta, deer blood and sheep liver. Similarly it is reasonable to assume that proteins in tissues other than these can similarly be rendered insoluble by the ethanol pre-treatment process, to provide enrichment of the low molecular weight fractions in subsequent aqueous extracts.

[0091] The use of both dried and frozen deer velvet tissue in the new process has been exemplified. Similarly it is reasonable to assume that other tissues can be utilised in the new process in either a dried or a non-dried (i.e. frozen or fresh) state.

References

[0092]

Scopes, R.K. (1987) "Protein Purification, Principles and Practice, 2nd Edition", Springer Verlag, New York, p 38.

Tani, H., Kamidate, T. and Watanabe, H. (1997) "Micelle-mediated extraction", Journal of Chromatography A, 780: 229-241.

Betzing, H. and Lekim, D. (1975) "Process of manufacturing enzyme preparation rich in lipase", Patent GB1454983.

Claims

1. A process for isolating low molecular weight ("LMW") peptides from tissue *in situ* comprising the steps of:

- a) homogenizing the tissue;
- b) mixing the homogenized tissue with an organic solvent to form a fully-wetted slurry;
- c) standing or agitating the slurry to denature the proteins *in situ* within the tissue;
- d) removing the organic solvent from the tissue;
- e) mixing the organic solvent-treated tissue of step d) with a sufficient volume of water or an aqueous solution to extract the peptides;
- f) separating a liquid extract from the tissue residue of step e) to obtain an aqueous solution containing the low molecular weight peptide fraction removed from the tissue.

2. A process as claimed in claim 1 wherein prior to undertaking step a) the tissue is dried in a pre-step.

3. A process as claimed in claim 2 wherein the tissue is freeze dried.

4. A process as claimed in claim 1 wherein the organic solvent of step b) is ethanol.

5. A process as claimed in either claim 1 or claim 4 wherein the organic solvent in step b) is 70% ethanol.

6. A process as claimed in either claim 1 or claim 4 wherein the organic solvent in step b) is ethanol having a concentration

of substantially between 50% - 80% ethanol.

7. A process as claimed in either claim 1 or claim 4 wherein the organic solvent in step b) is ethanol having a concentration of substantially between 60% - 70% ethanol.

8. A process as claimed in claim 1 wherein the organic solvent of step b) is absolute ethanol which is added to the homogenized tissue to provide a total water content of approximately 30% with respect to the volume of ethanol.

9. A process as claimed in claim 1 wherein at step c) the slurry is allowed to stand or is agitated for a period of at least substantially 1 hour.

10. A process as claimed in claim 1 wherein at step c) the slurry is left to stand or is agitated for a period of substantially 3 hours or more.

11. A process as claimed in either claim 9 or claim 10 wherein the slurry is left to stand or is agitated at an ambient temperature between 10-30°C.

12. A process as claimed in claim 1 comprising additional step d1) wherein the solvent treated tissue of step d) is fully dried prior to undertaking step e).

13. A process as claimed in either claim 1 or claim 12 wherein the organic solvent-treated tissue of steps d) or d1) is mixed with water or aqueous solution for substantially 1 hour.

14. A process as claimed in claim 13 wherein the mixing is performed at an ambient temperature which does not exceed 30°C.

15. A process as claimed in claim 1 comprising additional step g) wherein steps e) to f) are repeated one or more times, to improve the yield of liquid extract from the tissue residue of step e).

16. A process as claimed in either claim 1 or claim 15 wherein the liquid extract from steps f) or g) is dried to obtain a low molecular weight peptide extract.

17. An isolated mixture of low molecular weight peptides obtained by the process of claim 1.

18. The use of an organic solvent to denature proteins *in situ* within tissue as part of an extraction process to isolate a low molecular weight peptide extract from tissue.

19. An isolated mixture of low molecular weight peptides obtained from deer velvet.

Patentansprüche

1. Verfahren zum Isolieren von niedermolekularen ("LMW") Peptiden aus Gewebe *in situ*, umfassend folgende Schritte:

- a) Homogenisieren des Gewebes;
- b) Mischen des homogenisierten Gewebes mit einem organischen Lösemittel, um einen vollständig benetzten Schlamm zu bilden;
- c) Ruhen lassen oder Umrühren des Schlamms, um die Proteine *in situ* innerhalb des Gewebes zu denaturieren;
- d) Entfernen des organischen Lösemittels aus dem Gewebe;
- e) Mischen des mit dem organischen Lösemittel behandelten Gewebes aus Schritt d) mit einer ausreichenden Menge von Wasser oder wässriger Lösung, um die Peptide abzutrennen;
- f) Trennen eines Flüssigextrakts von dem Geweberückstand aus Schritt e), um eine wässrige Lösung zu erzielen, welche die Fraktion niedermolekularer Peptide enthält, die aus dem Gewebe entfernt wurde.

2. Verfahren nach Anspruch 1, wobei vor dem Ausführen von Schritt a) das Gewebe in einem vorbereitenden Schritt getrocknet wird.

3. Verfahren nach Anspruch 2, wobei das Gewebe gefriergetrocknet wird.

EP 1 606 232 B1

4. Verfahren nach Anspruch 1, wobei das organische Lösemittel aus Schritt b) Ethanol ist.
5. Verfahren nach Anspruch 1 oder Anspruch 4, wobei das organische Lösemittel aus Schritt b) 70%iges Ethanol ist.
- 5 6. Verfahren nach Anspruch 1 oder Anspruch 4, wobei das organische Lösemittel in Schritt b) Ethanol mit einer Konzentration von im Wesentlichen zwischen 50 % und 80 % Ethanol ist.
7. Verfahren nach Anspruch 1 oder Anspruch 4, wobei das organische Lösemittel in Schritt b) Ethanol mit einer Konzentration von im Wesentlichen zwischen 60 % und 70 % Ethanol ist.
- 10 8. Verfahren nach Anspruch 1, wobei das organische Lösemittel aus Schritt b) reines Ethanol ist, das zu dem homogenisierten Gewebe hinzugefügt wird, um einen Gesamtwassergehalt von ungefähr 30 % im Verhältnis zur Ethanolmenge bereitzustellen.
- 15 9. Verfahren nach Anspruch 1, wobei in Schritt c) der Schlamm während eines Zeitraums von mindestens im Wesentlichen 1 Stunde ruhen gelassen oder umgerührt wird.
10. Verfahren nach Anspruch 1, wobei in Schritt c) der Schlamm während eines Zeitraums von im Wesentlichen 3 Stunden ruhen gelassen oder umgerührt wird.
- 20 11. Verfahren nach Anspruch 9 oder 10, wobei der Schlamm auf einer Umgebungstemperatur zwischen 10 und 30 °C ruhen gelassen oder umgerührt wird.
12. Verfahren nach Anspruch 1, umfassend den zusätzlichen Schritt d1), in dem das mit dem Lösemittel aus Schritt d) behandelte Gewebe vor der Ausführung von Schritt e) vollständig getrocknet wird.
- 25 13. Verfahren nach Anspruch 1 oder Anspruch 12, wobei das mit dem organischen Lösemittel aus Schritt d) oder d1) behandelte Gewebe im Wesentlichen 1 Stunde lang mit Wasser oder einer wässrigen Lösung gemischt wird.
- 30 14. Verfahren nach Anspruch 13, wobei die Mischung auf einer Umgebungstemperatur erfolgt, die nicht über 30 °C hinausgeht.
15. Verfahren nach Anspruch 1, umfassend den zusätzlichen Schritt g), wobei die Schritte e) bis f) ein oder mehrere Male wiederholt werden, um den Ertrag des Flüssigextrakts des Geweberückstands aus Schritt e) zu verbessern.
- 35 16. Verfahren nach Anspruch 1 oder Anspruch 15, wobei der Flüssigextrakt aus Schritt f) oder g) getrocknet wird, um einen niedermolekularen Peptidextrakt zu erzielen.
17. Isolierte Mischung aus niedermolekularen Peptiden, erzielt durch das Verfahren nach Anspruch 1.
- 40 18. Verwendung eines organischen Lösemittels zum Denaturieren der Proteine in situ innerhalb eines Gewebes im Rahmen eines Extraktionsverfahrens, um einen niedermolekularen Peptidextrakt aus dem Gewebe zu isolieren.
19. Isolierte Mischung aus niedermolekularen Peptiden, die aus Hirschbast erzielt wird.
- 45

Revendications

- 50 1. Processus permettant d'isoler des peptides de faible poids moléculaire (« LMW ») de tissus in situ, comprenant les étapes consistant à
- a) homogénéiser les tissus ;
- b) mélanger les tissus homogénéisés avec un solvant organique pour former une pâte entièrement mouillée ;
- c) laisser reposer ou brasser la pâte pour dénaturer les protéines in situ à l'intérieur des tissus ;
- 55 d) enlever le solvant organique des tissus ;
- e) mélanger les tissus traités au solvant organique issus de l'étape d) avec un volume suffisant d'eau ou de solution aqueuse pour extraire les peptides ;
- f) séparer un extrait liquide des résidus de tissus issus de l'étape e) pour obtenir une solution aqueuse contenant

la fraction de peptides de faible poids moléculaire enlevée des tissus.

2. Processus selon la revendication 1, dans lequel, avant exécution de l'étape a), les tissus sont séchés au cours d'une étape préliminaire.

3. Processus selon la revendication 2, dans lequel les tissus sont lyophilisés.

4. Processus selon la revendication 1, dans lequel le solvant organique de l'étape b) est de l'éthanol.

5. Processus selon la revendication 1 ou la revendication 4, dans lequel le solvant organique à l'étape b) est de l'éthanol à 70 %.

6. Processus selon la revendication 1 ou la revendication 4, dans lequel le solvant organique à l'étape b) est de l'éthanol ayant une concentration substantiellement entre 50 % et 80 % d'éthanol.

7. Processus selon la revendication 1 ou la revendication 4, dans lequel le solvant organique à l'étape b) est de l'éthanol ayant une concentration substantiellement entre 60 % et 70 % d'éthanol.

8. Processus selon la revendication 1, dans lequel le solvant organique de l'étape b) est de l'éthanol pur qui est ajouté aux tissus homogénéisés pour obtenir une teneur en eau totale d'environ 30 % par rapport au volume d'éthanol.

9. Processus selon la revendication 1, dans lequel à l'étape c), on laisse reposer la pâte ou on la brasse pendant une période d'au moins substantiellement 1 heure.

10. Processus selon la revendication 1, dans lequel à l'étape c), on laisse reposer la pâte ou on la brasse pendant une période d'au moins substantiellement 3 heures.

11. Processus selon la revendication 9 ou la revendication 10, dans lequel on laisse reposer la pâte ou on la brasse à une température ambiante entre 10 et 30 °C.

12. Processus selon la revendication 1, comprenant l'étape supplémentaire d1) dans lequel le tissu traité au solvant, issu de l'étape d), est entièrement séché avant exécution de l'étape e).

13. Processus selon la revendication 1 ou la revendication 12, dans lequel le tissu traité au solvant organique, issu des étapes d) ou d1), est mélangé avec de l'eau ou une solution aqueuse pendant substantiellement 1 heure.

14. Processus selon la revendication 13, dans lequel le mélange est effectué à une température ambiante qui ne dépasse pas les 30 °C.

15. Processus selon la revendication 1, comprenant l'étape supplémentaire g), dans lequel les étapes e) à f) sont répétées une ou plusieurs fois afin d'améliorer le rendement d'extrait liquide du résidu de tissus issu de l'étape e).

16. Processus selon la revendication 1 ou la revendication 15, dans lequel l'extrait liquide des étapes f) ou g) est séché pour obtenir un extrait de peptides de faible poids moléculaire.

17. Mélange isolé de peptides de faible poids moléculaire, obtenu par le processus selon la revendication 1.

18. Utilisation d'un solvant organique pour dénaturer des protéines in situ à l'intérieur de tissus dans le cadre d'un processus d'extraction afin d'isoler un extrait de peptides de faible poids moléculaire des tissus.

19. Mélange isolé de peptides de faible poids moléculaire obtenu du velours de cerf.

FIGURE 1

Gel filtration chromatography profile of (a) deer velvet total protein extract. (b) deer velvet LMW extract prepared using the new *in situ* extraction process. An approximate molecular weight scale is given below the chromatograms.




FIGURE 2

A LMW extract prepared by precipitation of high molecular weight proteins from deer velvet total protein extract by addition of cold ethanol in the liquid phase.




FIGURE 3

Gel filtration chromatography profiles of freeze-dried deer velvet samples extracted with 0.05M phosphate buffer (pH 6.9) following pre-treatment for 3 hours with a 6:1 (v/w) ratio of 30%, 40%, 50%, 60%, 70%, 80% or 90% ethanol, or without pre-treatment (0% ethanol).




FIGURE 4

A graph showing the effect of pre-treatment of freeze-dried deer velvet samples with 30%, 40%, 50%, 60%, 70%, 80% or 90% ethanol (6:1 v/v), prior to extraction with 0.05M phosphate buffer (pH 6.9), on the total areas of peaks of low and of high molecular weight proteins in the extract solutions.




FIGURE 5

Gel filtration chromatography profiles of freeze-dried deer velvet samples extracted with 0.05M phosphate buffer (pH 6.9) following pre-treatment for 16.5 hours with a 6:1 (v/w) ratio of 30%, 40%, 50%, 60%, 70%, 80% or 90% ethanol, or without pre-treatment (0% ethanol).




FIGURE 6

A graph showing the effect of time of incubation used for the pre-treatment of freeze-dried deer velvet samples with 70% ethanol, prior to extraction with 0.05M phosphate buffer (pH 6.9), on the total areas of peaks of low and of high molecular weight proteins in the extract solutions.




FIGURE 7

A graph showing the effect of the ratio (v/w) of the 70% ethanol used for 3 hour pre-treatment of freeze-dried deer velvet samples, prior to extraction with 0.05M phosphate buffer (pH 6.9), on the total areas of peaks of low and of high molecular weight proteins in the extract solutions.




FIGURE 8

Gel filtration chromatography profiles of freeze-dried deer velvet samples extracted with 0.05M phosphate buffer (pH 6.9) following pre-treatment for 3 hours with a 6:1 (v/w) ratio of 70% acetonitrile, 70% acetone, 70% propan-2-ol, 70% ethanol or 70% methanol, or without pre-treatment with organic solvent.




FIGURE 9

Gel filtration chromatography profiles of freeze-dried deer velvet samples extracted with various buffers (each 0.05M) or with 0.05M sodium chloride or water, following pre-treatment for 3 hours with a 6:1 (v/w) ratio of 70% ethanol.




FIGURE 10

Gel filtration chromatography profiles of freeze-dried deer placenta samples extracted with 0.05M phosphate buffer (pH 6.9) following pre-treatment for 3 hours with a 6:1 (v/w) ratio of 30%, 40%, 50%, 60%, 70%, 80% or 90% ethanol, or without pre-treatment (0% ethanol).




FIGURE 11

Gel filtration chromatography profiles of freeze-dried deer blood samples extracted with 0.05M phosphate buffer (pH 6.9) following pre-treatment for 3 hours with a 6:1 (v/w) ratio of 30%, 40%, 50%, 60%, 70%, 80% or 90% ethanol, or without pre-treatment (0% ethanol).




FIGURE 12

Gel filtration chromatography profiles of freeze-dried sheep liver samples extracted with 0.05M phosphate buffer (pH 6.9) following pre-treatment for 3 hours with a 6:1 (v/w) ratio of 30%, 40%, 50%, 60%, 70%, 80% or 90% ethanol, or without pre-treatment (0% ethanol).




FIGURE 13

Gel filtration chromatography profiles of freeze-dried sheep liver samples extracted with various buffers (each 0.05M) or with water, following pre-treatment for 3 hours with a 6:1 (v/v) ratio of 70% ethanol.





FIGURE 14

Gel filtration chromatography profiles of frozen and of freeze-dried deer velvet samples extracted with 0.05M phosphate buffer (pH 6.9) following pre-treatment for 3 hours with a 6:1 (v/w) ratio of 70% ethanol, compared to a sample of freeze-dried deer velvet similarly extracted without ethanol pre-treatment.



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6093402 A [0010]
- EP 0273121 A [0010]
- WO 9700269 A [0010]
- GB 1454983 A [0092]

Non-patent literature cited in the description

- **Scopes, R.K.** Protein Purification, Principles and Practice. Springer Verlag, 1987, 38 [0092]
- **Tani, H. ; Kamidate, T. ; Watanabe, H.** Micelle-mediated extraction. *Journal of Chromatography A*, 1997, vol. 780, 229-241 [0092]